On Monday, Lineage Cell Therapeutics Inc (AMEX: LCTX) opened higher 6.46% from the last session, before settling in for the closing price of $0.68. Price fluctuations for LCTX have ranged from $0.37 to $1.15 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 45.08%. Company’s average yearly earnings per share was noted -9.73% at the time writing. With a float of $227.36 million, this company’s outstanding shares have now reached $228.36 million.
Considering the fact that the conglomerate employs 77 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 97.15%, operating margin of -223.1%, and the pretax margin is -169.12%.
Lineage Cell Therapeutics Inc (LCTX) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lineage Cell Therapeutics Inc is 0.44%, while institutional ownership is 48.65%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -9.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.01% during the next five years compared to -2.93% drop over the previous five years of trading.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Check out the current performance indicators for Lineage Cell Therapeutics Inc (LCTX). In the past quarter, the stock posted a quick ratio of 3.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.08, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.05 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Compared to the last year’s volume of 1.5 million, its volume of 1.11 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 47.92%. Additionally, its Average True Range was 0.04.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 89.57%, which indicates a significant increase from 85.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 97.84% in the past 14 days, which was higher than the 84.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5052, while its 200-day Moving Average is $0.6581. Nevertheless, the first resistance level for the watch stands at $0.7465 in the near term. At $0.7742, the stock is likely to face the second major resistance level. The third major resistance level sits at $0.8084. If the price goes on to break the first support level at $0.6846, it is likely to go to the next support level at $0.6504. Now, if the price goes above the second support level, the third support stands at $0.6227.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
There are currently 228,356K shares outstanding in the company with a market cap of 164.15 million. Presently, the company’s annual sales total 9,500 K according to its annual income of -18,610 K. Last quarter, the company’s sales amounted to 1,500 K and its income totaled -4,140 K.
